Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7249-7257

  Arce, Mariana P ^a   Rodríguez Franco, María Isabel ^a   González Muñoz, Gema C ^a   Pérez, Concepción ^a   López, Beatriz ^a   Villarroya, Mercedes ^b   López, Manuela G ^b   García, Antonio G ^b   Conde, Santiago ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMINO ACID DERIVATIVE; AMYLOID BETA PROTEIN; ANION; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE; ESTER DERIVATIVE; FREE RADICAL; GLUTAMIC ACID DERIVATIVE; N 4 BROMOTHIENO 2 YL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; N 6 CHLOROBENZO[B]THIENO 2 YL ACETYL GLUTAMINE[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; N BENZOYL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; N BENZO[B]THIENO 2 YL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; N BOC GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 IL)ETHYL] O NHEX; N CBZ GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 IL)ETHYL] O NHEX; N PYRIDIN[2,3 B]THIENO 2 YL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL) O NHEX; N THIENO 2 YL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; N THIENO[2,3 B]THIENO 2 YL GLUTAMIC ACID[NH 2 (1 BENZYLPIPERIDIN 4 YL)ETHYL] O NHEX; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PROPIDIUM IODIDE; TROLOX C; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CATALYSIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; MITOCHONDRION; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PHARMACOPHORE;

EID: 70949098148     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900628z     Document Type: Article

References (48)

1. Alzheimer's Association, 2009 Alzheimer's Disease Facts and Figures. http://www.alz.org/national/documents/report-alzfactsfigures2009.pdf
2. Sloane, P. D.; Zimmerman, S.; Suchindran, C.; Reed, P.; Wang, L.; Boustani, M.; Sudha, S. The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu. Rev. Public Health 2002, 23, 213-231.
3. Butterfield, D. A.; Reed, T.; Newman, S. F.; Sultana, R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radical Biol. Med. 2007, 43, 658-677.
4. Conde, S. beta-Amyloid peptide as a target for treatment of Alzheimer's disease. Expert Opin. Ther. Pat. 2002, 12, 503-512.
5. Smith, D. G.; Cappai, R.; Barnham, K. J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta 2007, 1768, 1976-1990.
6. Shcherbatykh, I.; Carpenter, D. O. The role ofmetals in the etiology of Alzheimer's disease. J. Alzheimers Dis. 2007, 11, 191-205. (Pubitemid 47010984)
7. Atwood, C. S.; Obrenovich, M. E.; Liu, T.; Chan, H.; Perry, G.; Smith, M. A.; Martins, R. N. Amyloid-beta: A chameleon walking in two worlds: A review of the trophic and toxic properties of amyloid-beta. Brain Res. Rev. 2003, 43, 1-16.
8. Tabner, B. J.; El-Agnaf, O. M.; Turnbull, S.; German, M. J.; Paleologou, K. E.; Hayashi, Y.; Cooper, L. J.; Fullwood, N. J.; Allsop, D. Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J. Biol. Chem. 2005, 280, 35789-35792.
9. Leuner, K.; Hauptmann, S.; Abdel-Kader, R.; Scherping, I.; Keil, U.; Strosznajder, J. B.; Eckert, A.; Müller, W. E. Mitochondrial dysfunction: The first domino in brain aging and Alzheimer's disease? Antioxid. Redox Signaling 2007, 9, 1659-1675. (Pubitemid 47462969)
10. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des. 2006, 12, 4377-4387.
11. Holzgrabe, U.; Kapková, P.; Alptüzün, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets 2007, 11, 161-179.
12. Castro, A.; Conde, S.; Rodríguez-Franco, M.I.; Martínez, A. Noncholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease. Mini-Rev. Med. Chem. 2002, 2, 37-50.
13. Grutzendler, J.; Morris, J. C. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001, 61, 41-52.
14. Darvesh, S.; Hopkins, D. A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 4, 131-138.
15. Greig, N. H.; Utsuki, T.; Yu, Q.; Zhu, X.; Holloway, H. W.; Perry, T.; Lee, B.; Ingram, D. K.; Lahiri, D. K.Anew therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 159-165.
16. Alvarez, A.; Opazo, C.; Alarcón, R.; Garrido, J.; Inestrosa, N. C. Acetylcholinesterase promotes the aggregation of amyloid-betapeptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 1997, 272, 348-361.
17. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416.
18. Johnson, G.; Moore, S. W. The adhesion function on acetylcholinesterase is located at the peripheral anionic site. Biochem. Biophys. Res. Commun. 1999, 258, 758-762.
19. Muñoz-Ruiz, P.; Rubio, L.; García-Palomero, E.; Dorronsoro, I.; del Monte-Millán, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Medina, M.; Martínez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: New disease-modifying agents for Alzheimer's disease. J. Med. Chem. 2005, 48, 7223-7233.
20. http://www.noscira.com
21. Bolognesi, M. L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, C. Alzheimer's disease: New approaches to drug discovery. Curr. Opin. Chem. Biol. 2009, 13, 303-308.
22. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheime's disease. Angew. Chem., Int. Ed. 2007, 46, 3689-3692. (Pubitemid 46981250)
23. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Castro, A.;Martínez, A. Design and synthesis of N-benzylpiperidine purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. Bioorg. Med. Chem. 2005, 13, 6795-6802.
24. Conde, S.; Pérez, D. I.; Martínez, A.; Pérez, C.; Moreno, F. J. Thienyl and phenyl alpha-halomethyl ketones: New inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. J. Med. Chem. 2003, 46, 4631-4663.
25. Martínez, A.; Fernández, E.; Castro, A.; Conde, S.; Rodríguez- Franco,M. I.;Baños, J.-E.; Badía, A. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinones as new acethylcholinesterase inhibitors. Eur. J. Med. Chem. 2000, 35, 913-922.
26. Rodríguez Franco, M. I.; San Lorenzo, P.; Martínez, A.; Navarro, P. Selective dopamine receptors: Synthesis, complexing properties, and molecular modelling studies of new podands derived from 4-hydroxy-1H-pyrazole. Tetrahedron 1999, 55, 2763-2772. (Pubitemid 29090530)
27. Rodríguez-Franco, M. I.; Fierros, M.; Martínez, A.; Navarro, P.; Conde, S. Selective carriers of norepinephrine and ammonium ions: Ionophoric properties and molecular modelling studies of diester crown compounds containing a 1,3-bis(1H-pyrazol-1-yl)- propane unit. Bioorg. Med. Chem. 1997, 5, 363-367.
28. Fernández-Bachiller, M. I.; Pérez, C.; Campillo, N. E.; Páez, J. A.; González-Muñoz, G. C.; Usán, P.; García-Palomero, E.; López, M. G.; Villarroya, M.; García, A. G.; Martínez, A.; Rodríguez- Franco, M. I. Tacrine - melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. Chem. Med. Chem. 2009, 4, 828-841.
29. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 2006, 49, 459-462.
30. Martínez, A.; Lanot, C.; Pérez, C.; Castro, A.; López-Serrano, P.; Conde, S. Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: N-Benzylpiperidine amino acid derivatives. Bioorg. Med. Chem. 2000, 8, 731-738.
31. 2. Bioorg. Med. Chem. Lett. 2003, 13, 1011-1014.
32. Ellman,G.L.;Courtney,K.D.;Andres,V., Jr.;Feather-Stone,R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95.
33. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001, 40, 10447-10457.
34. Inestrosa, N. C.; Alvarez, A.; Pérez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996, 16, 881-891. (Pubitemid 26124065)
35. Taylor, P.; Lappi, S. Interaction of fluorescence probes with acetylcholinesterase: The site and specifity of propidium binding. Biochemistry 1975, 14, 1989-1997.
36. Marco-Contelles, J.; León, R.; López, M. G.; García, A. G.; Villarroya, M. Synthesis and biological evaluation of new 4H-pyrano[ 2,3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals and cause neuroprotection against calcium overload and free radicals. Eur. J. Med. Chem. 2006, 41, 1464-1469.
37. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 2003, 38, 223-232.
38. Reviriego, F.; Rodríguez-Franco, M. I.; Navarro, P.; García- España, E.; Liu-González, M.; Verdejo, B.; Domènech, A. The sodium salt of diethyl 1H-pyrazole-3,5-dicarboxylate as an efficient amphiphilic receptor for dopamine and amphetamines. Crystal structure and solution studies. J. Am. Chem. Soc. 2006, 128, 16458-16459.
39. Pavón, F. J.; Hernández-Folgado, L.; Bilbao, A.; Cippitelli, A.; Jagerovic, N.; Abellán, G.; Rodríguez-Franco, M. I.; Serrano, A.; Macías, M.; Navarro, M.; Goya, P.; Rodríguez de Fonseca, F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H- 1,2,4-triazole - LH 21. Neuropharmacology 2006, 51, 358-366.
40. Marco-Contelles, J.; León, R.; de los Ríos, C.; Samadi, A.; Bartolini, M.; Andrisano, V.; Huertas, O.; Barril, X.; Luque, F. J.; Rodríguez-Franco, M. I.; López, B.; López, M. G.; García, A. G.; Carreiras, M. C.; Villarroya, M. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. J. Med. Chem. 2009, 52, 2724-2732.
41. Camps, P.; Formosa, X.; Galdeano, C.; Muñoz-Torrero, D.; Ramírez, L.;Gómez, E.; Isambert, N.; Lavilla, R.; Badía, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and β-amyloid-directed anti-Alzheimer compounds. J. Med. Chem. 2009, 52, 5365-5379.
42. Newhouse, K.; Hsuan, S. L.; Chang, S. H.; Cai, B.; Wang, Y.; Xia, Z. Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol. Sci. 2004, 79, 137-146.
43. 2+ oscillations induced by veratridine. Eur. J. Pharmacol. 1994, 270, 331-339.
44. Arias, E.; Alés, E.; Gabilán, N. H.; Cano-Abad, M. F.; Villarroya, M.; García, A. G.; López, M. G. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004, 46, 103-114.
45. Arias, E.; Gallego-Sandín, S.; Villarroya, M.; García, A. G.; López, M. G. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J. Pharmacol. Exp. Ther. 2005, 315, 1346-1353.
46. Orozco, C.; García-de-Diego, A. M.; Arias, E.; Hernández-Guijo, J. M.; García, A. G.; Villarroya, M.; López, M. G. Depolarization preconditioning produces cytoprotection against veratridine-induced chromaffin cell death. Eur. J. Pharmacol. 2006, 553, 28-38.
47. León, R.; De los Ríos, C.; Marco-Contelles, J.; López, M. G.; García, A. G.; Villarroya, M. Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death. Eur. J. Med. Chem. 2008, 43, 668-674.
48. Valero, T.; Del Barrio, L.; Egea, J.; Cañas, N.; Martínez, A.; García, A. G.; Villarroya, M.; López, M. G. NP04634 prevents cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells. Eur. J. Pharmacol. 2009, 607, 47-53.